Compare ECPG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECPG | CANF |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 4.7M |
| IPO Year | 1999 | 2011 |
| Metric | ECPG | CANF |
|---|---|---|
| Price | $68.96 | $3.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $77.33 | ★ $9,750.00 |
| AVG Volume (30 Days) | 255.6K | ★ 643.0K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 287.14 | N/A |
| EPS | ★ 10.91 | N/A |
| Revenue | ★ $1,768,802,000.00 | N/A |
| Revenue This Year | $4.53 | $461.72 |
| Revenue Next Year | $4.76 | $290,391.28 |
| P/E Ratio | $6.31 | ★ N/A |
| Revenue Growth | ★ 34.37 | N/A |
| 52 Week Low | $26.45 | $0.17 |
| 52 Week High | $74.58 | $10.40 |
| Indicator | ECPG | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 35.07 |
| Support Level | $65.01 | $0.59 |
| Resistance Level | $74.58 | $4.74 |
| Average True Range (ATR) | 2.17 | 0.20 |
| MACD | -0.33 | -0.08 |
| Stochastic Oscillator | 55.45 | 0.85 |
Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.